Final Results of a phase III trial of celecoxib (C) in addition to standard chemotherapy for advanced NSCLC with COX- 2 overexpression: CALGB 30801 (Alliance) Edelman, Martin J. , Wang, Xiaofei , Hodgson, Lydia ... - MSTO - Int. J. Radiat. Oncol. Biol. Phys. - 2017 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30801
Long-term Survival of Patients (pts) Treated with High-dose Radiotherapy(rt) and Concurrent Chemotherapy for Unresectable Non-small Cell Lung Cancer (nsclc) Schild, S. , Hillman, S. , Graham, D. , Vora, S. , Garces, Y. ... - MSTO - J Thorac Oncol - 2012 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Respiratory - NCCTG-N0028
Switch Maintenance with Sunitinib (S) in Advanced Non-Small Cell Lung Cancer (NSCLC): An Alliance (CALGB 30607), Randomized, Placebo-controlled Phase III Trial Socinski, Mark A. , Wang, Xiaofei F. , Baggstrom, Maria Quintos ... - MSTO - Int. J. Radiat. Oncol. Biol. Phys. - 2014 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30607
